Norepinephrine is used to treat severe low blood pressure, typically in hospital settings when other treatments haven't worked. It works by narrowing blood vessels and strengthening the heart's contractions to increase blood pressure.[2] Levophed is currently approved and in use across 28 indications[4].[1]
Levophed is one of 604 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
160 competitors in Hypertension
Levophed
Foundayo
Nitrostat
Baxfendy
Alka-Seltzer
HCP1803-3
SGLT2
Avastin
Winrevair
Alphagan
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 13, 1950
LEVOPHED
NDA NDA007513
Feb 14, 1977
LEVOPHED
NDA NDA007513
Apr 14, 1978
LEVOPHED
NDA NDA007513
Jan 14, 1985
LEVOPHED
NDA NDA007513
May 27, 1987
LEVOPHED
NDA NDA007513
Mar 2, 1988
LEVOPHED
NDA NDA007513
Apr 6, 1989
LEVOPHED
NDA NDA007513
Jun 12, 1991
LEVOPHED
NDA NDA007513
Sep 13, 1991
LEVOPHED
NDA NDA007513
Sep 20, 1999
LEVOPHED
NDA NDA007513
Sep 26, 2007
LEVOPHED
NDA NDA007513
Jun 15, 2020
LEVOPHED
NDA NDA007513
Oct 21, 2020
LEVOPHED
NDA NDA007513
Sources
Details